Forte Biosciences (FBRX) Free Cash Flow (2016 - 2026)

Forte Biosciences (FBRX) has 11 years of Free Cash Flow data on file, last reported at -$18.8 million in Q1 2026.

• On a quarterly basis, Free Cash Flow fell 80.49% year-over-year to -$18.8 million in Q1 2026; TTM through Mar 2026 was -$59.4 million, a 72.05% decrease from a year earlier, with the FY2025 full-year figure at -$51.0 million, down 65.73% from the prior year.
• Free Cash Flow for Q1 2026 stood at -$18.8 million, down from -$16.5 million in the prior quarter.
• Over the last five years, Free Cash Flow for FBRX reached as high as -$1.4 million in Q2 2022 and fell as low as -$18.8 million in Q1 2026.
• Historically, Free Cash Flow has averaged -$8.1 million across 5 years, with a median of -$8.1 million in 2024.
• Across the five-year window, Free Cash Flow soared 65.03% in 2022 and plunged 369.02% in 2023, its largest moves.
• Year by year, Free Cash Flow stood at -$2.9 million in 2022, then plunged by 210.61% to -$9.0 million in 2023, then declined by 11.73% to -$10.0 million in 2024, then tumbled by 64.18% to -$16.5 million in 2025, then fell by 14.05% to -$18.8 million in 2026.
• Per Business Quant data, the three most recent Free Cash Flow figures were -$18.8 million in Q1 2026, -$16.5 million in Q4 2025, and -$14.1 million in Q3 2025.